ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Growing evidence shows that mutant p53 proteins, which are present in many human tumors, gain oncogenic activities that can actively contribute to tumorigenesis. Mutant p53 proteins have been extensively shown to affect the expression of several genes involved in various aspects of cancer biology. We show here the ChIP-on-chip analysis of mutant p53 binding to a set of 154 promoters, composed of both validated and putative mutant p53 target genes. By using the chromatin obtained from mutant p53R175H-immunoprecipitation in proliferating SKBr3 breast cancer cells, we found that mutant p53 binds to 40 of the 154 promoters analyzed. siRNA-mediated mutant p53 knock-down modulates the transcript abundance of some of these target genes. Two-thirds of the mutant p53-bound promoters were also engaged by either p300 or PCAF acetyl-transferases, strongly indicating the presence of transcriptionally active complexes. We also found that NF-kB binding sites are overrepresented among the mutant p53-bound promoters; a ChIP-on-chip analysis confirmed that NF-kB p65 binds to 27 of the mutant p53-bound promoters, indicating that mutant p53 could influence the transcriptional output of these NF-kB target genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · cited 1×
“Such activities are commonly described as mutant p53 gain-of-function (GOF) (reviewed in Brosh and Rotter, 2009; Oren and Rotter, 2010).”
Self-citationTP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes
Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884 · cited 2×
“…are more frequent in advanced stage cancer or in cancer subtypes with aggressive behavior (Langerod et al., 2007; Wang et al., 2004a, 2004b) and have been consistently associated with poor prognosis in cancers such as breast, colorectal, head and neck, and leukemia (Petitjean et al., 2007).”
p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878 · cited 1×
“…genes included in the mutp53-chip design are known to be regulated by both wild-type and mutant p53 proteins, mostly in opposite ways; one example is FAS (CD95), which is upregulated by wtp53 (Muller et al., 1998; Owen-Schaub et al., 1995) and downregulated by mutant p53 (Zalcenstein et al., 2003).”
Self-citationDi Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418 · cited 4×
“…have previously re-ported that mutant p53 reaches target gene promoters through the interaction with sequence-specific transcription factors, such as NF-Y, E2F1, NF-kB, and Vitamin D receptor (Di Agostino et al., 2006; Fontemaggi et al., 2009, 2010; Stambolsky et al., 2010; Weisz et al., 2007).”
InfluentialSelf-citationModulation of the Vitamin D3 Response by Cancer-Associated Mutant p53
Stambolsky, P., Tabach, Y., Fontemaggi, G., Weisz, L., Maor-Aloni, R., Sigfried, Z., Shiff, I., Kogan, I., Shay, M., Kalo, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.025 · Cited by 245 · cited 5×
“Very recently, mutant p53 was also found to differentially modulate subsets of VDR target genes and to convert vitamin D into an antiapoptotic agent (Stambolsky et al., 2010).”
InfluentialSelf-citationZalcenstein, A., Stambolsky, P., Weisz, L., Müller, M., Wallach, D., Goncharov, T. M., Krammer, P. H., Rotter, V., & Oren, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206724 · Cited by 123 · cited 1×
“…genes included in the mutp53-chip design are known to be regulated by both wild-type and mutant p53 proteins, mostly in opposite ways; one example is FAS (CD95), which is upregulated by wtp53 (Muller et al., 1998; Owen-Schaub et al., 1995) and downregulated by mutant p53 (Zalcenstein et al., 2003).”
Self-citation
Cited by
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
The diverse and complex roles of NF-κB subunits in cancer
Perkins, N. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3204 · Cited by 852
Cooks, T., Pateras, I. S., Tarcic, O., Solomon, H., Schetter, A. J., Wilder, S., Lozano, G., Pikarsky, E., Forshew, T., Rozenfeld, N., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.022 · Cited by 466
Self-citationKim, M. P., & Lozano, G. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.185 · Cited by 311
Metadata
- Authors
- Dell'Orso, S., Fontemaggi, G., Stambolsky, P., Goeman, F., Voellenkle, C., Levrero, M., Strano, S., Rotter, V., Oren, M., & Blandino, G.
- Venue
- OMICS: A Journal of Integrative Biology
- Publisher
- SAGE Publications
- Published
- 2011-05
- Volume
- 15
- Issue
- 5
- Pages
- 305-312
- ISSN
- 1536-2310 (ISSN-L)
- 1557-8100
- OpenAlex
- W1974007183
- Cited by
- 42
- References
- 6
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters. https://app.cochat.ai/papers/10.1089/omi.2010.0084
- The paper
- Dell'Orso, S., Fontemaggi, G., Stambolsky, P., Goeman, F., Voellenkle, C., Levrero, M., Strano, S., Rotter, V., Oren, M., & Blandino, G. (2011). ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters. OMICS: A Journal of Integrative Biology. https://doi.org/10.1089/omi.2010.0084
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.